Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Melvin I. Marks is active.

Publication


Featured researches published by Melvin I. Marks.


Clinical Pediatrics | 1993

Clinical Profile of Pediatric Patients Hospitalized With Respiratory Syncytial Virus Infection

William V. La Via; Steven W. Grant; Harris R. Stutman; Melvin I. Marks

To update the clinical profile of pediatric patients hospitalized with RSV infection, we retrospectively reviewed the records of 246 children (male:female ratio 1.44:1) admitted during one season to a tertiary-care hospital. The most common admitting diagnoses were bronchiolitis (37.4%), pneumonia (32.5%), and possible septicemia (13%). Median age was 3 months; median length of stay, three days. Twice as many minorities were admitted with RSV infection as all other admissions during the same year. Family history of asthma, while common (35%), did not affect length of stay or complications. Of the 38 (15%) patients requiring intensive care, 29 (76%) underwent ventilation. Patients with underlying cardiopulmonary disease had more complications, were more likely to require intensive care (about 50%), and had significantly longer hospital stays than others. All three patients (1.2%) who died had congenital heart disease. Common risk factors included young age, chronic cardiopulmonary disease, male sex, and possibly family history of asthma. Although the most typical clinical diagnoses remain bronchiolitis and pneumonia, a systemic illness resembling the sepsis syndrome has emerged at our institution as a significant clinical presentation.


The Journal of Pediatrics | 1992

Vitamin A levels in children with measles in Long Beach, California

Antonio Arrieta; Margaret Zaleska; Harris R. Stutman; Melvin I. Marks

Studies from Africa suggest that vitamin A supplementation may reduce morbidity and mortality rates associated with measles among poorly nourished children. We studied 20 children with measles in Long Beach, Calif., and found that 50% (95% confidence interval; 28% to 72%) were vitamin A deficient. This frequency among presumably well nourished American children supports evaluation of vitamin A status as a part of acute management of measles in the United States.


Clinical Pediatrics | 1991

Bacterial Meningitis—An Update

Melvin I. Marks

This report emphasizes new clinical information about bacterial meningitis in infants and children. Important elements of diagnosis include examination for the presence of shock and increased intracranial pressure. In such cases, initial treatment should focus on appropriate fluid therapy, administration of oxygen, reduction of intracranial pressure and use of corticosteroids. Currently, antibiotics of choice include ampicillin plus either cefotaxime or ceftriaxone in young infants, and one of these cephalosporins in older patients (beyond 3 months of age). Shorter durations of therapy (5 to 7 days for meningococcus, 7 days for haemophilus and 7-10 days for pneumococcus) are now commonly employed. In many centers, dexamethasone is started before the first dose of antibiotic and continued for 4 days to reduce neurologic and audiologic sequelae. Future trends will include studies of endotoxin neutralizers and non-steroidal anti-inflammatory drugs to reduce further tissue injury in meningitis. Prevention of meningitis is the ultimate goal. Since Haemophilus influenzae vaccination can now begin at 2 months, this approach may bring important results soon.


American Journal of Infection Control | 1990

Invasive Haemophilus influenzae type B infections: A continuing challenge

Hillel K. Janai; Harris R. Stutman; Melvin I. Marks

Invasive Haemophilus influenzae type b infections are a major cause of severe infections in children between 2 months and 5 years of age. Meningitis, arthritis, pneumonia, cellulitis, osteomyelitis, and epiglottitis affect approximately 25,000 patients annually and are a major cause of mortality and morbidity in children. H. influenzae type b clinical syndromes, diagnostic methods, epidemiology, immunity, and treatment are discussed in this review. Although potent antibiotics have long been available for treatment, mortality and morbidity rates have not declined substantially in the last 15 years. Prevention of disease is therefore a continuous medical challenge. Secondary cases can be prevented by identification of the high-risk groups and the application of appropriate techniques, including antimicrobial prophylaxis. Primary prevention is the major goal of current research. H. influenzae type b vaccines currently are available for protection of infants 18 months of age and older. Prevention of primary and secondary disease and future developments, including new vaccine strategies, are stressed.


Clinical Pediatrics | 1993

Respiratory Syncytial Virus Infection: The Expanded Clinical Spectrum

Melvin I. Marks

Hospital in Long Beach, California. Interestingly, similar numbers of patients were hospitalized (218 and 267, respectively), and similar percentages (14% and 13%, respectively) of patients presented with a syndrome compatible with possible septicemia. Hypothermia was the only manifestation of RSV disease in 6% of patients in the Cleveland study and was noted in patients younger than 30 days old. 1


Clinical Pediatrics | 1993

Endobronchial Tuberculosis Presenting as Respiratory Failure in an Infant

Antonio Arrieta; Melvin I. Marks; Luis M. Franchi; J. Carlos Maggi; Carl Muchnick

can cause ventricular tachycardia and fibrillation, seizures, and vasoconstriction with hypertension as well as nausea, vomiting, and diarrhea. Our patient on presentation demonstrated vomiting with loose stools. Although he had been exposed in utero, no evidence of neurologic dysfunction was documented on his delivery physical. A developmental exam after recovery and before discharge was appropriate for a 5-month-old infant. Cravey reported two infants de-


The Journal of Pediatrics | 2002

Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial.

Harris R. Stutman; Jay M. Lieberman; Eliezer Nussbaum; Melvin I. Marks


The Journal of Pediatrics | 1992

Respiratory syncytial virus puzzle: Clinical features, pathophysiology, treatment, and prevention

William V. La Vla; Melvin I. Marks; Harris R. Stutman


Journal of Antimicrobial Chemotherapy | 1991

In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid

Adriano G. Arguedas; Antonio Arrieta; Harris R. Stutman; J C Akaniro; Melvin I. Marks


The Journal of Pediatrics | 1987

Secondary rates of Haemophilus influenzae type b disease among day care contacts

Melvin I. Marks; Wendy L. Dorchester

Collaboration


Dive into the Melvin I. Marks's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Antonio Arrieta

Children's Hospital of Orange County

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carl Muchnick

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hillel K. Janai

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

J C Akaniro

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge